- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07838324
A Pilot Investigation of Pain Reprocessing Therapy for Functional Dyspepsia
The purpose of this research is to test whether pain processing therapy, a novel psychological intervention that emphasizes exposure-based techniques, can reduce digestive symptom severity and improve functioning in people with functional dyspepsia.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Jonah Pedelty
- Telefonnummer: 507-538-7774
- E-post: Pedelty.Jonah@mayo.edu
Studiesteder
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic
-
Ta kontakt med:
- Jonah Pedelty
- Telefonnummer: 507-538-7774
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Fulfilled Rome V diagnostic criteria for functional dyspepsia postprandial distress syndrome subtype, with or without epigastric pain syndrome.
- A total score of at least 3 on the Gastroparesis Cardinal Symptom Index (GCSI) indicating symptom severity to be moderate or higher.
- Normal gastric emptying as confirmed by standard gastric emptying testing (if such a testing was clinically done).
- Upper endoscopy negative to rule out structural or organic etiologies for GI symptoms (within last 1 year).
- Fluent in English language.
- Able to provide informed consent and comply with study procedures.
Exclusion Criteria:
- Evidence of organic gastrointestinal disease or surgical history that could explain participant symptoms (e.g., peptic ulcer disease, celiac disease, inflammatory bowel disease, eosinophilic gastritis or eosinophilic esophagitis, malignancy).
- Current or recent (within the past 12 months) eating disorder such as anorexia nervosa or bulimia nervosa. Historical eating disorder diagnosis may also be exclusionary if residual disordered eating patterns, fear of weight gain, or food-related body image concerns are judged by the investigator to potentially confound symptom interpretation or participation.
- Underweight BMI (<17 kg/m²) or evidence of clinically significant unintentional weight loss (>25% body weight in 6 months).
- Current use of enteral or parenteral nutrition for >50% of caloric needs and/or participant unwillingness to reduce use of enteral or parenteral nutrition at the time of study enrollment.
- History of developmental or intellectual disability, current cognitive impairment that would preclude participation, or other neurological illness impairing cognitive functioning.
- Active suicidal ideation, suicide attempt within the past 12 months, severe psychiatric illness, severe depressive symptomatology, acute distress, or other symptomatology that, in the investigator's judgment, would necessitate a different level of psychiatric care and/or prevent full engagement in psychological intervention sessions or adherence to study procedures.
- Medical disability or any unstable systemic illness (e.g., decompensated hepatic, cardiac, renal, or neurological disease) that could interfere with participation, comprehension, or safety in psychological intervention sessions.
- Current daily cannabis use (inhaled, edible, or medical). Other substance use or misuse of prescription medications may also be exclusionary if substance use patterns are judged by the investigator to potentially confound symptom interpretation or participation.
- Current pregnancy or lactation.
- Inability or unwillingness of individual to give informed consent.
- Non-fluent in English, or any condition that would limit compliance or follow-up.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Pain Reprocessing Therapy
Participants will receive eight weekly pain reprocessing therapy sessions. Session 1 will occur at Week 0, and sessions will continue weekly through Session 8 at Week 7. The first and last sessions will be delivered in person when possible to coordinate with baseline and post-treatment physiologic testing, and interim sessions will be completed via telehealth. |
Pain reprocessing therapy is a psychological intervention designed to help patients reconceptualize chronic symptoms in functional dyspepsia as related to changes in brain-gut communication. Treatment includes education about the neuroscience of chronic symptoms, development of a personalized understanding of symptom mechanisms, interoceptive exposure using mindfulness and safety reappraisal, approaches to reduce symptom-related fear and avoidance, techniques for addressing psychosocial threat factors, and strategies to increase positive emotional experiences. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Average Gastroparesis Cardinal Symptom Index Score
Tidsramme: Baseline, Week 7
|
Change in average Gastroparesis Cardinal Symptom Index score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire will be assessed. The Gastroparesis Cardinal Symptom Index assesses upper gastrointestinal symptom severity; higher scores indicate greater symptom severity. |
Baseline, Week 7
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Maximum Tolerated Volume During Nutrient Drink Test
Tidsramme: Baseline, Week 7
|
Change in maximum tolerated volume consumed during the nutrient drink test will be assessed. Maximum tolerated volume is the total volume of nutrient drink consumed before the participant reaches the protocol-defined stopping point. |
Baseline, Week 7
|
|
Change in Symptom Ratings During Nutrient Drink Test
Tidsramme: Baseline, Week 7
|
Change in standardized symptom ratings collected during the nutrient drink test will be assessed. Symptoms may include fullness, nausea, bloating, and abdominal pain, with higher scores indicating greater symptom severity. |
Baseline, Week 7
|
|
Change in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life Score
Tidsramme: Baseline, Week 7
|
Change in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life score will be assessed. The questionnaire measures disease-specific quality of life in participants with upper gastrointestinal disorders; higher scores indicate better quality of life. |
Baseline, Week 7
|
|
Mean Change From Baseline in Gastrointestinal Unhelpful Thinking Scale Pain Catastrophizing Subscale Score
Tidsramme: Baseline, Week 7
|
Gastrointestinal-specific pain catastrophizing will be assessed using the Pain Catastrophizing subscale of the Gastrointestinal Unhelpful Thinking Scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in gastrointestinal-specific pain catastrophizing. |
Baseline, Week 7
|
|
Mean Change From Baseline in Visceral Sensitivity Index Score
Tidsramme: Baseline, Week 7
|
Gastrointestinal-specific anxiety will be assessed using the Visceral Sensitivity Index. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in gastrointestinal-specific anxiety. |
Baseline, Week 7
|
|
Mean Change From Baseline in Fear of Food Questionnaire Score
Tidsramme: Baseline, Week 7
|
Food-related fear and avoidance will be assessed using the Fear of Food Questionnaire. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in food-related fear and avoidance. |
Baseline, Week 7
|
|
Mean Change From Baseline in Nine Item ARFID Screen Fear Subscale Score
Tidsramme: Baseline, Week 7
|
Restrictive eating behaviors related to fear of aversive consequences will be assessed using the fear subscale of the Nine Item ARFID Screen. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in fear-related restrictive eating behaviors. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Physical Function Score
Tidsramme: Baseline, Week 7
|
General physical function will be assessed using the PROMIS Physical Function scale. Mean scores will be calculated at baseline and following completion of treatment. A positive change from baseline indicates improvement in physical function. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Anxiety Score
Tidsramme: Baseline, Week 7
|
Anxiety will be assessed using the PROMIS Anxiety scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in anxiety. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Depression Score
Tidsramme: Baseline, Week 7
|
Depression will be assessed using the PROMIS Depression scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in depression. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Fatigue Score
Tidsramme: Baseline, Week 7
|
Fatigue will be assessed using the PROMIS Fatigue scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in fatigue. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Sleep Disturbance Score
Tidsramme: Baseline, Week 7
|
Sleep disturbance will be assessed using the PROMIS Sleep Disturbance scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in sleep disturbance. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Ability to Participate in Social Roles and Activities Score
Tidsramme: Baseline, Week 7
|
Ability to participate in social roles and activities will be assessed using the PROMIS Ability to Participate in Social Roles and Activities scale. Mean scores will be calculated at baseline and following completion of treatment. A positive change from baseline indicates improvement in social participation. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Pain Interference Score
Tidsramme: Baseline, Week 7
|
Pain interference will be assessed using the PROMIS Pain Interference scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in pain interference. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Pain Intensity Score
Tidsramme: Baseline, Week 7
|
Pain intensity will be assessed using the PROMIS Pain Intensity numerical rating scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in pain intensity. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Anger Score
Tidsramme: Baseline, Week 7
|
Anger will be assessed using the PROMIS Anger scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in anger. |
Baseline, Week 7
|
|
Percentage of Participants Who Complete the Pain Reprocessing Therapy Intervention
Tidsramme: Baseline, Week 7
|
The percentage of enrolled participants who complete all 8 planned pain reprocessing therapy sessions will be reported. |
Baseline, Week 7
|
|
Percentage of Participants Who Report Satisfaction With Pain Reprocessing Therapy
Tidsramme: Week 7
|
The percentage of participants who rate satisfaction with services as "mostly satisfied" or "very satisfied" on the Client Satisfaction Questionnaire-4 will be reported. |
Week 7
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Megan Petrick, PhD, Mayo Clinic
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 26-003631
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .